Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis

Annals of the Rheumatic Diseases

Volumn 75, Issue 12, 2016, Pages 2142-2149

  Ponsoye, Matthieu ^a   Frantz, Camelia ^a   Ruzehaji, Nadira ^a   Nicco, Carole ^a   Elhai, Muriel ^a   Ruiz, Barbara ^a   Cauvet, Anne ^a   Pezet, Sonia ^a   Brandely, Marie Laure ^b   Batteux, Frédéric ^a,b   Allanore, Yannick ^a   Avouac, Jérôme ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

Author keywords

Inflammation; Systemic Sclerosis; T Cells

Indexed keywords

ABATACEPT; BLEOMYCIN; INTERLEUKIN 10; INTERLEUKIN 6; IL10 PROTEIN, MOUSE; INTERLEUKIN-6, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFIBROTIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CB17 MOUSE; CELL INFILTRATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DERMATITIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; EXPERIMENTAL DERMAL FIBROSIS; EXPERIMENTAL FIBROSIS; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; SCID MOUSE; SCLERODERMA; SKIN DEFECT; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GRAFT VS HOST DISEASE; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; SCLERODERMA, SYSTEMIC; SKIN DISEASES; T LYMPHOCYTE;

ABATACEPT; ANIMALS; B-LYMPHOCYTES; BLEOMYCIN; DISEASE MODELS, ANIMAL; FIBROSIS; GRAFT VS HOST DISEASE; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MICE; SCLERODERMA, SYSTEMIC; SKIN DISEASES; T-LYMPHOCYTES;

EID: 84960193321     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208213     Document Type: Article

References (39)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009;5:200-6.
3. White B. Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 1996;22:695-708.
4. Gu YS, Kong J, Cheema GS, et al. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38:132-60.
5. Roumm AD, Whiteside TL, Medsger TA Jr, et al. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984;27:645-53.
6. Mavalia C, Scaletti C, Romagnani P, et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997;151:1751-8.
7. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
8. Varga J, Pasche B. Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol 2008;20:720-8.
9. Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006;297:333-44.
10. Sato S, Fujimoto M, Hasegawa M, et al. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2004;43:1261-6.
11. Balbi G, Ferrera F, Rizzi M, et al. Association of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis. Clin Exp Immunol 2007;149:40-7.
12. Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72: 1217-20.
13. de Paoli FV, Nielsen BD, Rasmussen F, et al. Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol 2014;43:342-5.
14. Yue D, Brintnell W, Mannik LA, et al. CTLA-4Ig blocks the development and progression of citrullinated fibrinogen-induced arthritis in DR4-transgenic mice. Arthritis Rheum 2010;62:2941-52.
15. Ruzehaji N, Avouac J, Elhai M, et al. Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis. Arthritis Res Ther 2015;17:145.
16. Avouac J, Elhai M, Tomcik M, et al. Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. Ann Rheum Dis 2013;72: 1089-98.
17. Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis 2015;75:883-90.
18. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009;60:219-24.
19. Kavian N, Servettaz A, Marut W, et al. Sunitinib inhibits the phosphorylation of PDGF-receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease. Arthritis Rheum 2012;64:1990-2000.
20. Morin F, Kavian N, Marut W, et al. Inhibition of EGFR tyrosine kinase by erlotinib prevents sclerodermatous graft-versus-host disease in a mouse model. J Invest Dermatol 2015;135:2385-93.
21. Desallais L, Avouac J, Fréchet M, et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther 2014;16:R157.
22. Avouac J, Fürnrohr BG, Tomcik M, et al. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. Arthritis Rheum 2011;63:800-9.
23. Avouac J, Palumbo K, Tomcik M, et al. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2012;64:1642-52.
24. Avouac J, Palumbo-Zerr K, Ruzehaji N, et al. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis. Arthritis Rheum 2014;66:3140-50.
25. Jiménez-Alvarez L, Arreola JL, Ramírez-Martínez G, et al. The effect of CTLA-4Ig, a CD28/B7 antagonist, on the lung inflammation and T cell subset profile during murine hypersensitivity pneumonitis. Exp Mol Pathol 2011;91:718-22.
26. Jansen D, Bannoudi R, Arens R, et al. Abatacept decreases disease activity in the absence of CD4+ T-cells in the collagen induced arthritis model. Ann Rheum Dis 2015;74(Suppl 2):208.
27. Rau FC, Dieter J, Luo Z, et al. B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion. J Immunol 2009;183:7661-71.
28. Kin NW, Sanders VM. CD86 stimulation on a B cell activates the phosphatidylinositol 3-kinase/Akt and phospholipase Cγ2/protein kinase Cαβ signaling pathways. J Immunol 2006;176:6727-35.
29. Cutolo M, Soldano S, Montagna P, et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res Ther 2009;11:R176.
30. Wenink MH, Santegoets KC, Platt AM, et al. Abatacept modulates proinflammatory macrophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation. Ann Rheum Dis 2012;71:80-3.
31. Saito E, Fujimoto M, Hasegawa M, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002;109:1453-62.
32. Wallace VA, Kondo S, Kono T, et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 1994;24:1463-6.
33. Phelps RG, Daian C, Shibata S, et al. Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6Pa/Pa mice. J Autoimmun 1993;6:701-18.
34. Dodig TD, Mack KT, Cassarino DF, et al. Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum 2001;44:723-7.
35. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-7.
36. Pieper J, Herrath J, Raghavan S, et al. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol 2013;14:34.
37. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
38. Huaux F, Louahed J, Hudspith B, et al. Role of interleukin-10 in the lung response to silica in mice. Am J Respir Cell Mol Biol 1998;18: 51-9.
39. Louis H, Le Moine A, Quertinmont E, et al. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. Hepatology 2000;31:381-90.